WealthTrust Axiom LLC raised its stake in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 3.9% during the second quarter, Holdings Channel reports. The firm owned 8,612 shares of the biopharmaceutical company’s stock after buying an additional 320 shares during the period. WealthTrust Axiom LLC’s holdings in Gilead Sciences were worth $718,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in the stock. Bank of Montreal Can purchased a new position in shares of Gilead Sciences during the second quarter valued at about $427,750,000. Investec Asset Management LTD purchased a new position in shares of Gilead Sciences during the first quarter valued at about $280,342,000. NN Investment Partners Holdings N.V. purchased a new position in shares of Gilead Sciences during the first quarter valued at about $180,268,000. Temasek Holdings Private Ltd increased its position in Gilead Sciences by 8.1% in the first quarter. Temasek Holdings Private Ltd now owns 13,830,516 shares of the biopharmaceutical company’s stock worth $1,270,471,000 after buying an additional 1,035,592 shares in the last quarter. Finally, Old Mutual Global Investors UK Ltd. increased its position in Gilead Sciences by 256.3% in the second quarter. Old Mutual Global Investors UK Ltd. now owns 1,156,623 shares of the biopharmaceutical company’s stock worth $96,485,000 after buying an additional 832,028 shares in the last quarter. 77.94% of the stock is currently owned by institutional investors.
Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded down 1.27% during mid-day trading on Friday, reaching $75.24. 11,149,150 shares of the company traded hands. The stock has a market capitalization of $99.29 billion, a PE ratio of 6.60 and a beta of 1.10. The stock’s 50 day moving average is $78.95 and its 200 day moving average is $85.05. Gilead Sciences Inc. has a 52-week low of $74.92 and a 52-week high of $111.11.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.02 by $0.06. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The business had revenue of $7.78 billion for the quarter, compared to analyst estimates of $7.80 billion. During the same quarter in the previous year, the firm posted $3.15 earnings per share. Gilead Sciences’s revenue was down 5.7% compared to the same quarter last year. On average, analysts anticipate that Gilead Sciences Inc. will post $11.76 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Thursday, September 29th. Investors of record on Friday, September 16th were given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 2.50%. The ex-dividend date of this dividend was Wednesday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 16.56%.
GILD has been the topic of a number of recent analyst reports. Jefferies Group increased their price target on shares of Gilead Sciences from $91.00 to $93.00 and gave the stock a “buy” rating in a research note on Wednesday. Piper Jaffray Cos. reaffirmed a “buy” rating and set a $108.00 price target on shares of Gilead Sciences in a research note on Monday, August 15th. Morgan Stanley reaffirmed a “hold” rating and set a $103.00 price target on shares of Gilead Sciences in a research note on Wednesday, June 15th. Berenberg Bank initiated coverage on shares of Gilead Sciences in a research note on Thursday, September 22nd. They set a “buy” rating on the stock. Finally, Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Sunday, July 10th. Ten analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $104.71.
In related news, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction on Thursday, September 22nd. The shares were sold at an average price of $81.84, for a total transaction of $409,200.00. Following the transaction, the executive vice president now owns 132,964 shares of the company’s stock, valued at $10,881,773.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John C. Martin sold 100,000 shares of the business’s stock in a transaction on Thursday, September 1st. The stock was sold at an average price of $77.48, for a total transaction of $7,748,000.00. Following the transaction, the insider now directly owns 3,287,810 shares in the company, valued at approximately $254,739,518.80. The disclosure for this sale can be found here. Corporate insiders own 1.40% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.